Antonin Schmitt - Concepedia

Author

Antonin Schmitt

Centre Georges François Leclerc ORCID

Also Known As

A Schmitt, A. Schmitt, Antonin Schmitt, Audrey Saint-Ghislain, Samir Messaoudi, Schmitt, Antonin

Publications

878

Citations

H-Index

Concepts

All Affiliations

Centre Georges François Leclerc Inserm Université de Bourgogne Institut Claudius Regaud CHU Dijon Bourgogne

About

Antonin Schmitt is an author at Centre Georges François Leclerc specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	339
2	Cell Biology	2	2	81
3	Health Sciences	1	1	15
4	Public Health	1	1	15
5	Biostatistics	1	1	20

Antonin Schmitt

Publications

606

Citations

H-Index

Page 1

	Year	Citations
5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer Katarzyna Morawska, Françoise Goirand, Laurine Marceau, Oncotarget	2018	69
Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study Dejan Juric, Jordi Rodón, Ana M. González-Angulo, Cancer Research Chemoprevention StrategyPreliminary SafetyBayesian Regression ModelPharmacotherapyFirst-in-human Study	2012	61
A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients Antonin Schmitt, Laurence Gladieff, Amélie Lansiaux, Clinical Cancer Research	2009	57
Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure Antonin Schmitt, Laurence Gladieff, Céline M. Laffont, Journal of Clinical Oncology	2010	55
A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma Julia Jolibois, Antonin Schmitt, Bernard Royer Journal of Chromatography B BioanalysisMass SpectrometryPharmacologyFast Lc-ms/ms MethodHuman Plasma	2019	49
Improved stability of lipiodol–drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin Mathieu Boulin, Antonin Schmitt, E. Delhom, European Radiology Pharmaceutical ScienceDrug TargetingTransarterial ChemoembolisationMedicineHepatocellular Carcinoma Results	2015	42
BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study Dejan Juric, Jordi Rodón, AM Gonzalez-Angulo, Cancer Research MedicineReceptor Tyrosine KinasePreliminary SafetyPharmacotherapyAnti-cancer Agent	2012	39
Idarubicin-Loaded ONCOZENE Drug-Eluting Embolic Agents for Chemoembolization of Hepatocellular Carcinoma: In Vitro Loading and Release and In Vivo Pharmacokinetics Boris Guiu, Antonin Schmitt, Sven Reinhardt, Journal of Vascular and Interventional Radiology OncologyMedicineVitro LoadingVivo PharmacokineticsPharmacotherapy	2014	32
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours Hervé Rubie, Birgit Geoerger, Didier Frappaz, European Journal of Cancer Surgical OncologyTumoral PathologyMalignant DiseaseMedicinePathology	2010	26
Therapeutic drug monitoring as a tool to optimize 5-FU–based chemotherapy in gastrointestinal cancer patients older than 75 years Pauline Macaire, Katarzyna Morawska, Julie Vincent, European Journal of Cancer Therapeutic Drug MonitoringGastrointestinal OncologyMedicineCancer ManagementGastrointestinal Cancer Patients	2019	23

Page 1